MA33105B1 - Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase - Google Patents

Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase

Info

Publication number
MA33105B1
MA33105B1 MA34150A MA34150A MA33105B1 MA 33105 B1 MA33105 B1 MA 33105B1 MA 34150 A MA34150 A MA 34150A MA 34150 A MA34150 A MA 34150A MA 33105 B1 MA33105 B1 MA 33105B1
Authority
MA
Morocco
Prior art keywords
phenyl
inhibitors
phosphodiesterase
pyridin
benzoic acid
Prior art date
Application number
MA34150A
Other languages
Arabic (ar)
English (en)
Inventor
Gabriele Amari
Elisabetta Armani
Maurizio Delcanale
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33105(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA33105B1 publication Critical patent/MA33105B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES INHIBITEURS DE L'ENZYME PHOSPHODIESTÉRASE 4 (PDE4). PLUS PARTICULIÈREMENT, L'INVENTION CONCERNE DES COMPOSÉS QUI SONT DÉRIVÉS D'ALCOOLS 1-PHÉNYL-2-PYRIDINYL ALKYLIQUES, DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS LES COMPRENANT, LEURS COMBINAISONS ET LEURS UTILISATIONS THÉRAPEUTIQUES. DANS LA FORMULE (I), N REPRÉSENTE O OU 1; R1 ET R2 PEUVENT ÊTRE IDENTIQUES OU DIFFÉRENTS, ET SONT SÉLECTIONNÉS DANS LE GROUPE CONSTITUÉ PAR: - ALKYLE C1-C6 LINÉAIRE OU RAMIFIÉ; - OR3 OÙ R3 REPRÉSENTE ALKYLE C1-C6 ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU PLUSIEURS GROUPES CYCLOALKYLES C3-C7; ET - HNSO2R4 OÙ R4 REPRÉSENTE ALKYLE C1-C4 ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU PLUSIEURS ATOMES D'HALOGÈNE OU PAR UN GROUPE C1-C4, R1 ET/OU R2 REPRÉSENTANT HNSO2R4. LES AUTRES VARIABLES SONT TELLES QUE DÉFINIES DANS LES REVENDICATIONS.
MA34150A 2009-02-06 2010-02-04 Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase MA33105B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09001660A EP2216327A1 (fr) 2009-02-06 2009-02-06 Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
PCT/EP2010/000676 WO2010089107A1 (fr) 2009-02-06 2010-02-04 Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase

Publications (1)

Publication Number Publication Date
MA33105B1 true MA33105B1 (fr) 2012-03-01

Family

ID=40674203

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34150A MA33105B1 (fr) 2009-02-06 2010-02-04 Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase

Country Status (32)

Country Link
US (5) US8440834B2 (fr)
EP (2) EP2216327A1 (fr)
JP (2) JP5612610B2 (fr)
KR (1) KR101337728B1 (fr)
CN (1) CN102317262B (fr)
AR (1) AR075243A1 (fr)
AU (1) AU2010211274B2 (fr)
CA (1) CA2751494C (fr)
CL (1) CL2011001876A1 (fr)
CO (1) CO6400217A2 (fr)
CY (1) CY1113764T1 (fr)
EA (1) EA019113B1 (fr)
ES (1) ES2395528T3 (fr)
GE (1) GEP20135919B (fr)
HR (1) HRP20121004T1 (fr)
IL (1) IL214446A (fr)
JO (1) JO2761B1 (fr)
MA (1) MA33105B1 (fr)
ME (1) ME02325B (fr)
MX (1) MX2011007857A (fr)
MY (1) MY152048A (fr)
NZ (1) NZ594413A (fr)
PE (1) PE20120055A1 (fr)
PL (1) PL2393782T3 (fr)
PT (1) PT2393782E (fr)
RS (1) RS52605B (fr)
SG (1) SG173208A1 (fr)
SI (1) SI2393782T1 (fr)
TN (1) TN2011000346A1 (fr)
TW (1) TWI459945B (fr)
UA (1) UA102574C2 (fr)
WO (1) WO2010089107A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (fr) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase
EP2216327A1 (fr) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
EA024922B1 (ru) * 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
ES2628891T3 (es) * 2010-08-03 2017-08-04 Chiesi Farmaceutici S.P.A. Formulación farmacéutica que comprende un inhibidor de fosfodiesterasa
PH12013502516A1 (en) * 2011-06-06 2017-08-23 Chiesi Farm Spa Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN103827088B (zh) * 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
KR20140078719A (ko) 2011-10-21 2014-06-25 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
AR089232A1 (es) * 2011-12-16 2014-08-06 Chiesi Farma Spa Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia
KR20150022789A (ko) * 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
CN104837828B (zh) * 2012-12-05 2017-07-18 奇斯药制品公司 作为pde4‑抑制剂的苯基乙基吡啶衍生物
TR201807181T4 (tr) * 2012-12-05 2018-06-21 Chiesi Farm Spa Pde-4 i̇nhi̇bi̇törleri̇ ve muskari̇ni̇k reseptör antagoni̇stleri̇ olarak feni̇leti̇lpi̇ri̇di̇n türevleri̇
CA2893622A1 (fr) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Derives de phenylethylpyridine en tant qu'inhibiteurs de pde4
CA2893628C (fr) * 2012-12-05 2021-11-30 Chiesi Farmaceutici S.P.A. Derives d'alcool 1-phenyl-2-pyridinyl alkylique en tant qu'inhibiteurs de phosphodiesterase
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
AU2014339136C1 (en) * 2013-10-22 2019-10-31 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
WO2015082619A1 (fr) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Dérivés benzhydryle pour le traitement de maladies respiratoires
AR098621A1 (es) 2013-12-05 2016-06-01 Chiesi Farm Spa Derivados de heteroarilo
US9890151B2 (en) 2014-06-04 2018-02-13 Chiesi Farmaceutici S.P.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors
US10087176B2 (en) 2014-06-04 2018-10-02 Chiesi Farmaceutici S.P.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors
US9763924B2 (en) 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
US9326976B2 (en) * 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
US20190275022A1 (en) * 2016-07-20 2019-09-12 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
US20210038575A1 (en) 2017-12-28 2021-02-11 Chiesi Farmaceutici S.P.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
WO2020020957A1 (fr) 2018-07-27 2020-01-30 Chiesi Farmaceutici S.P.A. Nouvelles particules de support pour formulations de poudre sèche pour inhalation
CN115466169B (zh) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 取代邻苯二酚醚类化合物及其制备方法和应用
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
US20250288568A1 (en) 2022-04-27 2025-09-18 Chiesi Farmaceutici S.P.A. New crystal form of a pde4 inhibitor
WO2024027901A1 (fr) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4
CA3267958A1 (fr) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
AU2023347027A1 (en) 2022-09-22 2025-05-01 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
CA3268243A1 (fr) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025149100A2 (fr) * 2025-04-29 2025-07-17 北京泰德制药股份有限公司 Composition pharmaceutique contenant un composé a inhibiteur de pde4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (fr) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
DE602007012105D1 (de) * 2006-07-14 2011-03-03 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
EP2022783A1 (fr) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase
EP2070913A1 (fr) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase
EP2110375A1 (fr) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Inhibiteurs de la phosphodiestérase de type 4 appartenant à la classe tertiaire d'amine
EP2216327A1 (fr) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
EA024922B1 (ru) * 2010-08-03 2016-11-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
ES2628891T3 (es) * 2010-08-03 2017-08-04 Chiesi Farmaceutici S.P.A. Formulación farmacéutica que comprende un inhibidor de fosfodiesterasa
PH12013502516A1 (en) 2011-06-06 2017-08-23 Chiesi Farm Spa Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
KR20140078719A (ko) 2011-10-21 2014-06-25 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
KR20150022789A (ko) 2012-06-04 2015-03-04 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제로서 1-페닐-2-피리디닐 알킬 알코올의 유도체
CA2893628C (fr) 2012-12-05 2021-11-30 Chiesi Farmaceutici S.P.A. Derives d'alcool 1-phenyl-2-pyridinyl alkylique en tant qu'inhibiteurs de phosphodiesterase

Also Published As

Publication number Publication date
RS52605B (sr) 2013-04-30
WO2010089107A1 (fr) 2010-08-12
UA102574C2 (ru) 2013-07-25
AU2010211274A1 (en) 2011-08-25
CY1113764T1 (el) 2016-07-27
CL2011001876A1 (es) 2011-10-28
PE20120055A1 (es) 2012-02-16
US20100204256A1 (en) 2010-08-12
JP5612610B2 (ja) 2014-10-22
CN102317262A (zh) 2012-01-11
SG173208A1 (en) 2011-09-29
NZ594413A (en) 2013-05-31
BRPI1005695A2 (pt) 2017-06-06
JP2015038079A (ja) 2015-02-26
JO2761B1 (en) 2014-03-15
TN2011000346A1 (en) 2013-03-27
US8440834B2 (en) 2013-05-14
CN102317262B (zh) 2014-08-06
US8648204B2 (en) 2014-02-11
ES2395528T3 (es) 2013-02-13
EP2393782A1 (fr) 2011-12-14
BRPI1005695A8 (pt) 2017-12-26
GEP20135919B (en) 2013-09-10
TWI459945B (zh) 2014-11-11
PL2393782T3 (pl) 2013-02-28
US20140179647A1 (en) 2014-06-26
US9056176B2 (en) 2015-06-16
SI2393782T1 (sl) 2013-01-31
US20140378423A1 (en) 2014-12-25
IL214446A0 (en) 2011-09-27
MY152048A (en) 2014-08-15
EP2393782B1 (fr) 2012-09-12
US20130012487A1 (en) 2013-01-10
TW201032804A (en) 2010-09-16
HK1162508A1 (en) 2012-08-31
US20130289010A1 (en) 2013-10-31
IL214446A (en) 2014-12-31
US8859778B2 (en) 2014-10-14
EA019113B1 (ru) 2014-01-30
ME02325B (me) 2016-06-20
MX2011007857A (es) 2011-08-15
CA2751494A1 (fr) 2010-08-12
KR101337728B1 (ko) 2013-12-09
JP2012516863A (ja) 2012-07-26
AR075243A1 (es) 2011-03-16
AU2010211274B2 (en) 2016-03-17
CO6400217A2 (es) 2012-03-15
PT2393782E (pt) 2012-12-26
EP2216327A1 (fr) 2010-08-11
HRP20121004T1 (hr) 2012-12-31
CA2751494C (fr) 2017-03-07
KR20110094356A (ko) 2011-08-23
EA201190099A1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
TN2011000346A1 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
MA31919B1 (fr) Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif
CL2022002919A1 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
MA29909B1 (fr) Derives de pyridazine
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA33768B1 (fr) Triazolopyridines
MA34359B1 (fr) Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA35012B1 (fr) Composition phytosanitaire comprenant des huiles essentielles renforçant l'activité anti-fongique
MA29775B1 (fr) Derives de pyrazolone
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
EP4249070A3 (fr) Dérivés hétéroaryle bicycliques utilisés en tant qu'inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase